- Home
- NE vs ZLAB Comparison
NE vs ZLAB Comparison
Compare NE & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NE
- ZLAB
- Stock Information
- Founded
- NE 1985
- ZLAB 2013
- Country
- NE United States
- ZLAB China
- Employees
- NE N/A
- ZLAB N/A
- Industry
- NE Other Specialty Stores
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- NE Consumer Discretionary
- ZLAB Health Care
- Exchange
- NE Nasdaq
- ZLAB Nasdaq
- Market Cap
- NE 3.5B
- ZLAB 3.6B
- IPO Year
- NE N/A
- ZLAB 2017
- Fundamental
- Price
- NE $25.44
- ZLAB $29.76
- Analyst Decision
- NE Buy
- ZLAB Buy
- Analyst Count
- NE 8
- ZLAB 4
- Target Price
- NE $32.71
- ZLAB $47.37
- AVG Volume (30 Days)
- NE 2.1M
- ZLAB 944.8K
- Earning Date
- NE 04-28-2025
- ZLAB 05-08-2025
- Dividend Yield
- NE 8.07%
- ZLAB N/A
- EPS Growth
- NE N/A
- ZLAB N/A
- EPS
- NE 2.96
- ZLAB N/A
- Revenue
- NE $3,138,770,000.00
- ZLAB $418,326,000.00
- Revenue This Year
- NE $15.46
- ZLAB $44.07
- Revenue Next Year
- NE $2.46
- ZLAB $49.13
- P/E Ratio
- NE $8.36
- ZLAB N/A
- Revenue Growth
- NE 25.61
- ZLAB 43.72
- 52 Week Low
- NE $17.40
- ZLAB $16.01
- 52 Week High
- NE $48.74
- ZLAB $39.77
- Technical
- Relative Strength Index (RSI)
- NE 62.33
- ZLAB 44.77
- Support Level
- NE $24.60
- ZLAB $30.11
- Resistance Level
- NE $25.74
- ZLAB $31.34
- Average True Range (ATR)
- NE 0.80
- ZLAB 1.06
- MACD
- NE 0.11
- ZLAB -0.02
- Stochastic Oscillator
- NE 90.94
- ZLAB 36.04
About NE Noble Corporation plc A
Noble Corp PLC is an offshore drilling contractor for the oil and gas industry that provides contract drilling services to the international oil and gas industry with its fleet of mobile offshore drilling units. The company focuses on a high-specification fleet of floating and jackup rigs and the deployment of its drilling rigs in oil and gas basins around the world.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.